Renal transplantation: Cyclosporin A and antibody development after donor-specific transfusion  by Al-Muzairai, Ibrahim A. et al.
Kidney International, Vol. 35 (1989), PP. 105 7—1063
CLINICAL INVESTIGATION
Renal transplantation: Cyclosporin A and antibody
development after donor-specific transfusion
IBRAHIM A. AL-MUZAIRAI, ANDREW INNES, ANDREW HILLIs, KEITH N. STEWART,
JOHN M. BONE, GRAEME R.D. CATTO, and ALIsON M. MACLEOD
Departments of Medicine and Therapeutics, University of Aberdeen, Aberdeen, Scotland, and Royal Liverpool Hospital, Liverpool,
United Kingdom
Renal transplantation: Cyclosporin A and antibody development after
donor-specific transfusion. The survival of a one haplotype, mismatched
living-related renal allograft is improved by donor specific transfusion(DST) before transplantation although the mechanism is unclear. The
major risk of DST is sensitization of the recipient to donor lymphocytes
precluding transplantation. Fifty prospective recipients of a living
related transplant received either DST with cyclosporin A (group I) or
DST alone (group II). Persistent donor sensitization precluding trans-
plantation occurred in no patients in group I but in six in group II (P <
0.05). Ten of 14 of those who developed donor cytotoxicity had
previously been pregnant or received 10 third party transfusions
compared with II of 36 without such a history (P < 0.05). Alloantibod-
ies detected by a cellular ELISA developed following DST in 29%
patients and antiidiotypic antibodies detected by the short antiidiotypic
assay (SAA) in 36%; antiidiotypic activity occurred more frequently in
those given cyclosporin A (P < 0.02). Potentiating activity in the SAA
which occurred in sera from six patients after DST had no influence on
transplant outcome. Persistent sensitization, particularly in potential
transplant recipients who have been pregnant or received many trans-
fusions, can be prevented by giving cyclosporin A with DST; the
mechanisms of this effect may be the induction of antiidiotypic anti-
bodies. Both alloantibodies and antiidiotypic antibodies are induced by
DST and may protect a subsequent renal allograft from the specific
donor.
The survival of living-related renal transplants is better when
donor and recipient share both haplotypes than when only one
haplotype is shared [1]. Transplant outcome in this latter group
has been improved by blood transfusion from the specific donor
before transplantation [21. These transfusions may, however,
stimulate the development of cytotoxic antibodies to donor
lymphocytes in up to 30% of potential recipients; such sensiti-
zation precludes transplantation from that donor [3]. Immuno-
suppressive drugs including azathioprine [4] and cyclosporin A
have been administered along with transfusion [51 in an attempt
to reduce sensitization without impairing the beneficial transfu-
sion effect.
The mechanism of the transfusion effect is unclear, but it has
been suggested that transfusions are immunosuppressive and
may induce suppressor T lymphocytes [61, enhancing alloanti-
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bodies [7] or antiidiotypic antibodies [81. All these mechanisms
may be involved, and we have already shown in a small group
of patients that non-cytotoxic Fc receptor blocking alloanti-
bodies which are associated with improved transplant survival
can develop after donor specific transfusion administered both
with and without cyclosporin A [5]. In that study antibodies
were detected by a rosette inhibition assay, but recently we
have used a cellular enzyme-linked immunospecific assay
(CELISA), which is less time consuming to perform and is read
objectively [91.
Antiidiotypic antibodies (Ab2) directed to the variable region
of immunoglobulin form part of the idiotypic-antiidiotypic net-
work which is important in controlling antibody production and
activity [10]. They have been demonstrated in patients after
third party transfusion and their presence correlated with
improved allograft outcome [11]. Such antibodies are believed
to inhibit cytotoxic HLA antibodies (Abl). More recently
"potentiating" (Ab3) antibodies have also been detected [12].
In the present study, therefore, we investigated sera from 50
patients who received donor specific transfusion (DST) with
and without cyclosporin A to determine:
a) to what extent cyclosporin A administration along with
DST decreases sensitization to donor lymphocytes;
b) whether alloantibodies to donor lymphocytes detected by
CELISA are present after DST and;
c) whether antiidiotypic (Ab2) or potentiating (Ab3) antibod-
ies have developed to cytotoxic antibodies (Abl) directed




We studied 50 prospective recipients of a related donor
kidney, enrolled consecutively at the Royal Liverpool Hospital.
All received donor specific transfusion (DST) prior to transplan-
tation. Patients and prospective donors were tissue typed for
HLA A, B and DR antigens using conventional techniques [13].
Five patients were mismatched for both haplotypes and 45
matched for one haplotype with their donor; a positive, mixed
lymphocyte reaction was also noted between donor and recip-
ient lymphocytes in the latter group. Potential recipients were
randomized into two groups. Group I received 200 ml fresh
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blood eight, six and four weeks before transplantation and
cyclosporin A 10 mg/kg/day orally from nine weeks before
transplantation (N = 23). Group II received DST alone (N =
27). Serum samples were obtained before each transfusion and
two weeks after the last transfusion. One patient died as a result
of myocardial infarction and another rejected her graft after
eight months; both patients were in group II. All other grafts
were surviving at one year.
Target cells
Lymphocytes from all transfusion donors were prepared in
Liverpool by Ficoll sodium diatrizoate density gradient centrif-
ugation and separated into T and B lymphocytes using nylon
wool columns [14]. In addition further samples of heparinized
blood (20 ml) from 21 transfusion donors were flown to Aber-
deen where lymphocytes were freshly prepared for use in the
CELISA.
For use in the short antiidiotypic assay, T and B lymphocytes
were prepared from a panel of normal donors who possessed
the HLA-A, B and DR antigens of the transfusion donors which
were not shared with the potential recipients.
Sera
Sera from all 50 patients were tested in the complement
dependent cytotoxicity assay against donor T and B lympho-
cytes. Sera from 48 recipients obtained before each donor-
specific transfusion and two weeks after the last were heat
inactivated at 56°C for 45 minutes and ultracentrifuged at
100,000 g for 60 minutes to remove immune complexes before
storage at —70°C, All sera were tested in the complement-
dependent cytotoxicity assay and in the short antiidiotypic
assay; sera from 21 patients were assayed in CELISA.
Tissue typing sera to the HLA antigens not shared by donor
and recipient were obtained for the short antiidiotypic assay
(Behring, Middlesex, UK; United Kingdom Transplant Ser-
vice, Bristol, UK).
Preparation of the IgG fraction of serum
IgG fractions were prepared from two sera showing antiidio-
typic activity by protein A affinity chromatography [15, 16]. The
purity of the preparations was assessed by SDS polyacrylamide
gel electrophoresis, where a single band of molecular mass 150
to 160 kDa was noted. Two bands (52 kDa and 20 kDa) were
present when the gel was run under reducing conditions.
Experimental design
All test sera were assayed against peripheral blood lympho-
cytes (PBLs) from the transfusion donor to determine if com-
plement dependent cytotoxicity had been stimulated by the
DST program. Heparinized blood was freshly available from 21
transfusion donors. Recipient sera were tested in the cellular
ELISA to determine if non-complement binding antibodies to
lymphocytes from the transfusion donor had been stimulated by
the DST program. In order to select sera and target cells for the
short antiidiotypic assay the reactivity of the sera in CDC was
assayed against T and B lymphocytes prepared from the panel
of normal donors who possessed the HLA-A, B and DR
antigens of the transfusion donors not shared with the potential
recipients. Sera without detectable alloantibody activity in
CDC and cellular ELISA assays against appropriate target cells
were tested in the short antiidiotypic assay. Finally those sera
with potentiating antiidiotypic activity were tested in the anti-
human globulin complement-dependent cytotoxicity assay to
determine if weak cytotoxic activity could be detected.
Complement dependent cytotoxicity (CDC)
This assay was performed using the standard long incubation
two-stage NIH microlymphocytotoxicity assay with PBLs or an
enriched suspension of B lymphocytes as targets [13]. Lym-
phocytotoxicity was considered positive if cell kill was more
than 20% above background.
Cellular enzyme-linked immunospecfic assay (CELISA)
This assay was used to determine non-complement fixing
antibodies (a) to transfusion donor lymphocytes, and (b) to
target lymphocytes in sera showing inhibiting or potentiating
activity in the short antiidiotypic assay. It was performed
according to a modification [9] of the method of Morris, Thomas
and Hong [17]. Briefly, test sera and control sera from previ-
ously untransfused males (normal male serum-NMS) in dilu-
tions from neat to 1/8 were added to 10 d target PBLs or B cells
at a concentration of 5 x 106/ml in a V bottomed PVC microtiter
plate and incubated for 60 minutes at 22°C. The cells were
washed three times and after resuspension of the final cell
pellet, 20 d goat anti-human IgG-alkaline phosphatase (diluted
in PB S-2% BSA to a previously determined optimal concentra-
tion), was added to each well of a microtiter plate. The cells and
the conjugate were then incubated for 60 minutes at 22°C. After
three washes the cells were resuspended in 200 ,d 2 mt MgCI2
and the PVC plate snap-fitted to a polystyrene flat-bottomed
microtiter plate with wells previously coated with a 1 mg/mI
solution of poly-L-lysine. Holes punched in the apex of the
wells of the PVC plate allowed transfer of cells to the polysty-
rene plate by centrifugation for four minutes at 4°C. The MgCI2
was removed and 200 d I M diethanolamine buffer (pH 9.9)
containing 4 mg/ml p-nitrophenyl phosphate added to each well.
After incubation for 60 minutes at 37°C, 50 d of 3 M NaOH
were added to each well and the optical densities (OD) of the
well contents determined. The ratio
ODtest — ODceiis alone
ODNMS — ODcetjs alone
was calculated and accepted as positive if 2 [18].
Short antiidiotypic assay (SAA)
The short antiidiotypic assay was performed as described
previously [19]. Briefly a tissue typing serum directed towards
one of the donor HLA antigens not shared with the recipient
was serially diluted with recipient sera obtained both before
(pre) and after DST (post). Two microliters of the mixture was
then transferred to wells of microtest plates and incubated
overnight at 4°C. Panel target PBL or purified B lymphocytes (5
x 106/ml) bearing the unshared antigen were added to each well
and the standard long incubation, complement-dependent mi-
cro-lymphocytotoxicity assay performed. All tests were per-
formed in duplicate and the results read by an independent
observer.
Al-Muzairai et a!: Antibody development after blood transfusion 1059




T & B B
Transient Persistent Transient Persistent
Pregnancyor1OTPT









a Patients from group II (i.e. No CsA given)
Antiidiotypic activity was calculated as the percentage end-
point inhibition (EI%) using the formula [19]:
EI% [(Abl + Pre) — (Abi + Post)l ><
L (Abl + Pre) J
A difference of 50% El between the serum obtained before
DST (Abi + Pre) and the serum obtained after DST (Abi +
Post) was considered negative, while a difference of 50% El
was considered evidence of antiidiotypic activity.
Potentiating activity (Ab3) was considered to be present
when (Abi + Post) showed a 50% cell kill when compared
with (Abi + Pre) in the last dilution in which cytotoxic activity
was detected.
Anti-human globulin complement-dependent cytotoxicity
assay (AHG-CDC)
Non-cytotoxic sera with potentiating activity were tested in
AHG-CDC according to the method of Johnson, Rossen and
Butler [20]. Briefly, 2 d test sera were incubated with 2 p1
target lymphocytes at 5 x 106/ml in the wells of a Terasaki plate
for one hour at 22°C. The cells were washed three times in
RPM! with 10% FCS centrifuging for 1 minute at 1000 rpm. One
p! of 1/8 dilution of a a kappa AHG (Sigma Chemical Co, Poole,
Dorset, UK) was added to each well, and after three minutes 5
M' rabbit complement added. The plate was further incubated
for two hours at 22°C and cell death estimated by eosin dye
exclusion.
Statistical analysis
Statistical analyses were performed using x2 with Yates'
correction or Fisher's exact test.
Results
Cytotoxic antibody activity against donor lymphocytes
Sera from all 50 patients were tested against separated T and
B lymphocytes from the transfusion donor. Fourteen patients
(28%) became sensitized, six to both T and B lymphocytes and
eight to B cells alone. Six of 23 patients in group I and eight of
27 in group II became sensitized, but transplantation from the
specific donor was precluded in only six (12%) who developed
persistent antibodies; all of these patients belonged to group II
and received DST alone. The difference in incidence of such
persistent cytotoxicity between group I and group II was
statistically significant (P < 0.05).
Ten of the 14 patients who became sensitized had been
previously pregnant or received  10 third party transfusions
(TPT), whereas only 11 out of 36 of those who failed to develop
cytotoxicity had a history of such previous immunization (P <
Table 2. Antibodies detected by CELISA to donor lymphocytes
developing during the transfusion regime (19 patients studied)
CELISA +ve (donor PBL5) CELISA
—yeCytotoxicity Cytotoxicity
+ ye (donor — ye (donor (donor
PBLs) PBLs) PBLS)
DST+CsA 0 1 8
(Group I)
DST+alone 2 3 5
(Group II)
0.05, , with Yates' correction). Of the six patients in whom
antibody activity was persistent and transplantation cancelled,
all but one had been previously pregnant or received  10 TPT.
The difference in the incidence of persistent cytotoxicity be-
tween the two groups just failed to reach statistical significance
(x2 = 3.04).
The influence of cyclosporin A on the development of sensi-
tization in those with and without a history of previous immu-
nization by third party transfusion or pregnancy was also
assessed. Of the 21 patients with a history of previous preg-
nancy or who had been transfused at least 10 units of third party
blood, eight had received cyclosporin A and 13 had not. Five of
the 21 developed persistent sensitization and none had received
cyclosporin A, suggesting that cyclosporin A may be particularly
useful in preventing persistent sensitization in such patients; the
effect however was not statistically significant (Table 1).
Antibodies to transfusion donor lymphocytes detected by
CELISA
Lymphocyte samples from 21 transfusion donors were avail-
able for testing in CELISA. Antibody activity was detected in
sera from two of 10 patients in group I and six of 11 in group II.
Sera from one recipient in each group showed antibody activity
detected by CELISA before DST, and they were thus excluded
from analysis. Both these patients had previous third party
transfusion or had been pregnant. Data is thus available on 19
patients (Table 2). Activity developing after DST occurred iP
six (32%) patients one of whom had cyclosporin A and five of
whom had not. Sera from two patients in the latter group,
however, contained cytotoxic activity alone was thus detected
in four (2 1%) patients. The activity of these sera in SAA is given
below.
Antibodies detected by the short antiidiotypic assay (SAA)
Sera from 42 of 50 patients were tested in the SAA for
inhibitory activity using tissue typing sera as Abi containing
sera. Two patients were excluded from analysis as sera were
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Table 3. Antiidiotypic activity in sera from patient
with and without cyclosporin A




I II I and II Total activity absent
CyA + DST
(Group I)N = 14
DST alone 2 2
(Group H)N = 17
Total 5 4
(P < 0.02) Fisher's exact test
3 2 5 10 4
unavailable for study, and six because their sera were cytotoxic
to all panel target cells tested. Activity in the three sera
obtained after transfusion was compared with that in pre-
transfusion serum. Antibody activity was sought against cyto-
toxic sera to 43 donor class I antigens and 24 class II antigens
not shared with the recipients. Seventeen patients developed
inhibitory activity in the SAA. Sera from these patients were
negative in CDC against both donor lymphocytes and panel
lymphocytes selected to share HLA antigens with the donor;
these results indicated that the sera did not contain cytotoxic
alloantibodies to donor HLA antigens or to the other HLA
antigens on the panel target cells. Unless these sera had been
shown to have no non-cytotoxic binding activity to donor
lymphocytes in CELISA or in a rosette inhibition assay in a
previous study [5] they were tested against the selected panel
target lymphocytes in CELISA to exclude the presence of
non-cytotoxic antibodies to HLA antigens shared by the donor
and panel member. Five seralcell combinations from the three
patients showed activity in CELISA and were omitted from
analysis. All results in the SAA from three of these patients
(from group I) were thus excluded. In all 39 patients were
studied, 16 in group I and 23 in group II, 14 (36%) patients
developed antiidiotypic activity after DST. Ten showed poten-
tiating activity in the SAA (see below and Table 4), and sera
from two patients (group I) showed inhibitory activity against
cytotoxic sera to one and potentiating activity against another
HLA antigen. Sera from 17 patients showed neither inhibitory
nor potentiating activity.
The 14 patients who developed antiidiotypic activity were
compared with the 17 who failed to develop antibody activity
(Table 3). Ten in group I and four in group II, developed
antiidiotypic activity to HLA antibodies against at least one of
the donor HLA antigens not shared with the recipient. Four
patients in group I and 13 in group II failed to develop antibody
activity during DST. Inhibitory activity developed significantly
more frequently in those given cyclosporin A (10 of 14) with
DST than in those who received DST alone (4 of 17) (P < 0.02).
Of the 19 patients whose sera were non-cytotoxic and were
tested in CELISA against donor lymphocytes, four developed
activity following DST. One of these showed antiidiotypic
activity against cytotoxic HLA antisera to one unshared donor
antigen expressed on lymphocytes from a selected panel mem-
ber; CELISA against this target cell was negative. Four of the
19 patients showed antiidiotypic activity in the absence of
activity in CELISA. In all, therefore, eight of 19 (42%) patients
developed activity in at least one of the assays. IgG fractions of
sera from two patients with antiidiotypic activity were pre-
pared. Antiidiotypic activity was shown to reside in the IgG
fraction of serum (Fig. 1).
Sera from four patients in group I and six in group II appeared
to potentiate the cytotoxicity of tissue typing sera (Table 4).
None of these sera were cytotoxic to the panel target cells from
donors selected to share a given HLA antigen with the trans-
fusion donor, although sera from five patients were cytotoxic to
donor lymphocytes. Of the 10 patients showing potentiating
activity, two were excluded from analysis as alloantibody
binding was present in the CELISA to lymphocytes from both
the donor and all the selected panel members, or to cells from
the selected panel members when donor lymphocytes were
unavailable for testing in CELISA.
Some sera were shown to have cytotoxic activity to donor
lymphocytes but not to lymphocytes from panel members.
When these sera were tested in SAA the cytotoxic titer of tissue
typing sera was sometimes increased—mimicking potentiating
activity. We therefore wished to determine if this increase was
due to a low titer of cytotoxic antibodies in these sera not
detected by the standard CDC.
Since the AHG-CDC is thought to be a more sensitive assay
than the standard CDC, sera which were negative in the
standard CDC against selected panel target cells but showed
potentiating activity in the SAA were tested in AHG-CDC


















Patient 1 Patient 2
Fig. 1. End point inhibition (EI%) in the short antiidiotypic assay in
sera and serum fra ctions from 2 patients. Antiidiotypic activity resides
in the IgG fraction of serum. Symbols are: (E) whole serum, (0) IgG
fraction, (•) non-IgG fraction.
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Table 4. Alloantibody activity in sera showing potentiating activity in the short antiidiotypic assay (SAA)
Patient
DST + cyclosporine A (group I) DST alone (group II)
10 11 13 17 36 38 39 40 45 47
Potentiating activity in Al A2 Bl2 DR5 AlO A2 Al A3 A3 Bw6 DR7
SAA
Cytotoxicity against donor — — B — — — T + B T + B T + B B
T or B lymphocytes
CELISA against donor — — NT NT + — + + NT NT
lymphocytes
CELISA against selected — — — — — — — + — + +C
panel member's
lymphocytes'
AHG-CDC against selected — — + — — — — + + — +
panel member's
lymphocytes"
a NT not tested
b selected panel member was the same as that used in SAA
C all sera showed potentiating activity but only one showed activity in CELISA
Sera from all but one showed cytotoxicity against donor T and
B lymphocytes. When these sera as well as those demonstrating
positive activity in CELISA were removed from analysis,
potentiating activity in the SAA was present in sera from six
patients following DST (three from group I and three from
group II). Five of the six patients subsequently received a
transplant from their specific donor, and all grafts were surviv-
ing at one year.
Discussion
This study shows that following DST: (a) sensitization to
donor lymphocytes precluding transplantation occurred only in
recipients given DST without cyclosporin A; (b) sensitization
developed significantly more frequently in those who had been
previously pregnant or had been transfused at least 10 units of
third party blood; (c) non-cytotoxic alloantibodies detected by a
CELISA developed in 29% patients; (d) antiidiotypic activity to
HLA antibodies to donor antigens not shared with the recipient
developed in 36% of patients and was more frequently detected
in those who received cyclosporin A with DST; and (e) poten-
tiating activity the SAA occurred in five patients who subse-
quently received a successful transplant from the transfusion
donor.
Renal allograft survival in recipients of a one haplotype,
mismatched living-related transplant is undoubtedly better in
patients given DST than in untransfused recipients. Following
DST, however, up to 30% of such potential transplant recipi-
ents develop cytotoxic antibodies to donor lymphocytes neces-
sitating cancellation of the transplant [21. Sensitization was
reduced when oral azathioprine was administered with DST but
drug toxicity was noted in 60% of subjects [4]. In the present
study lymphocytotoxic antibodies to donor cells developed
following DST in approximately equal numbers of patients in
Groups I and II; donor sensitization disappeared within four
months in all those receiving cyclosporin A with DST, but only
in two of eight patients in the control group. After a short delay,
transplantation was performed in the patients in Group I, and in
all cases the grafts were functioning at one year despite the
positive crossmatch with the serum obtained immediately fol-
lowing DST. Renal transplantation from cadaver donors has
also been performed successfully when a stored serum gives a
positive crossmatch but the pretransplant serum is negative [21,
22]. The value of giving cyclosporine A with DST, therefore, is
thus not to decrease the overall incidence of donor sensitization
but to prevent the development of persistent cytotoxicity pre-
cluding successful transplantation.
A history of previous pregnancy or multiple third-party blood
transfusion is associated with the development of broad sensi-
tization [23]. Furthermore, sensitization following DST has
been shown to occur only in previously transfused patients and
the incidence of sensitization rises with the number of TPTs
given [24]. The present study shows a significantly higher
incidence of donor sensitization in those who had been previ-
ously pregnant or received 10 or more TPTs. All five of those in
this latter group who developed persistent sensitization had
been given DST without cyclosporin A. Although the results do
not achieve statistical significance, they suggest that cyclospo-
nfl A given with DST may be particularly useful in preventing
persistent sensitization in those with a previous history of high
levels of alloantigen exposure. Since only four of the 29 patients
without such histories developed donor sensitization (3 tran-
sient and 1 persistent) it was unclear whether cyclosporin A
given with DST was helpful in preventing sensitization in these
patients.
Why transfusions improve renal allograft survival is unclear,
but several mechanisms may be involved. We have already
shown that non-cytotoxic Fc receptor blocking antibodies oc-
cur after TPT [25] and after DST [5] irrespective of whether
cyclosporin A is given with the transfusions. The presence of
such antibodies in pre-transpiant sera correlates with improved
renal allograft survival particularly when recipients are less well
matched for HLA antigens with their donors [26, 27]. Further-
more, they are present during the first trimester in normal
primigravidae but not in women undergoing spontaneous abor-
tion [28], suggesting that they may protect both the semi-
allogenic fetus and a renal allograft. The development of Fc
receptor blocking activity cannot explain the beneficial transfu-
sion effect in all patients, and hence alloantibody activity,
detected by a CELISA, and antiidiotypic activity were sought
in sera obtained following DST.
Antibodies were detected by CELISA in sera from 29%
patients; sera from two patients were cytotoxic but is possible
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that both types of antibody co-exist in the same serum—
absorption studies would confirm this. Four patients had been
previously pregnant or received TPT, and thus, as with the
development of cytotoxic antibodies, previous immune stimuli
may induce a primary response while subsequent DST evokes a
secondary immune response. Non-cytotoxic alloantibodies
which are detected by CELISA are present during normal
pregnancy and may protect the developing fetus [91; they also
occur after DST and may represent one mechanism of the
beneficial transfusion effect.
Antiidiotypic antibodies occur after third party transfusion in
man [29] and in animal models [301, and have been suggested as
a possible mechanism of the beneficial transfusion effect in
renal transplantation (31); they are also present during normal
pregnancy [32]. Such antibodies have been detected using a
modification of the mixed lymphocyte reaction which takes five
days to perform and is thus unsuitable for assaying large
numbers of sera. Antiidiotypic activity has also been detected
by inhibition of lymphocytotoxicity using the F(ab']2 fragment
of the IgG fraction of serum obtained during pregnancy [331 or
after transfusion [34]. The SAA is a modification of the latter
assay in which antiidiotypic activity is sought in whole serum
rather than serum fractions; it can therefore be performed more
rapidly.
Using the SAA, antiidiotypic activity was detected following
DST in 36% patients. In the subgroup of patients whose sera
were tested in both CELISA and SAA, antiidiotypic activity
was noted in sera negative in CELISA. Clearly both types of
antibody could co-exist in the same serum, and absorption
studies would demonstrate this. Alloantibodies detected in
CELISA and antiidiotypic antibodies, in addition to the Fc
receptor blocking antibodies previously described [5], may be
induced by DST and play a role in protecting the subsequent
one haplotype, mismatched living-related transplant.
Antiidiotypic activity developed significantly more frequently
in those receiving cyclosporin A with DST than in those given
DST alone. We have already shown in an animal model [35] that
sensitization to class I antigens could be both prevented and
suppressed by administration of cyclosporin A and that antiid-
iotypic activity could be detected as the titer of class I alloreac-
tivity declined. In sensitized patients awaiting transplantation,
the broad spectrum of lymphocytotoxicity may narrow sponta-
neously, and it [36, 37] has shown that antiidiotypic antibodies
can develop as this happens. Taken together these results
suggest that the development of antiidiotypic activity may be
one mechanism by which titers of lymphocytotoxic antibodies
decline, and that cyclosporin A may promote such antibody
development, Furthermore, the immunosuppressive effect of
cyclosporin A may at least in part be due to the induction of
antiidiotypic antibodies.
Potentiating activity was noted in the SAA in six patients.
Such activity has been noted previously by others [12] in
non-cytotoxic pre-transpiant serum from patients whose stored
serum was cytotoxic to donor cells. In that report, only one of
10 grafts survived more than one month. In the present study
five of the six patients were grafted and all transplants were
surviving at one year. One patient became sensitized following
DST and transplantation from that donor cancelled. In patients
who have not been sensitized previously the development of
potentiating activity in the SAA after DST does not appear to
correlate with allograft failure.
The AHG-CDC has been suggested as a more sensitive form
of the standard microlymphocytotoxicity assay [20] and is
believed in 95% of cases to detect antibodies to defined HLA
specificities [38]. Activity in AHG-CDC was noted in sera
which were cytotoxic to donor lymphocytes but which con-
tained no cytotoxic antibodies to the panel target cell selected
to share a given HLA antigen with the transfusion donor. This
suggested that cytotoxicity to at least one donor antigen was
present in that serum. Others [39] also noted that the AHG-
CDC reaction was stronger in a serum cytotoxic to other cells.
It may be of value, therefore, to screen sera which show
potentiating activity in SAA and are cytotoxic to any other
target cell for binding activity in the AHG-CDC.
In conclusion, cyclosporin A given with DST prevents per-
sistent sensitization precluding transplantation, particularly in
patients who have been previously pregnant or have received
many transfusions. The development of antiidiotypic activity
may represent one of the humoral mechanisms by which
cyclosporin A prevents such sensitization. The presence of
potentiating activity in the SAA does not correlate with poor
allograft survival, and both alloantibodies and antiidiotypic
antibodies generated following DST may protect a subsequent
transplant.
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